Tharimmune, inc. announces closing of $11 million public offering

Bridgewater, nj / accesswire / november 30, 2023 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions, today announced the closing of its previously announced public offering of an aggregate of 11,000,000 shares of its common stock (or pre-funded warrants ("pre-funded warrants") in lieu thereof), including the partial exercise of the underwriter's over-allotment option. each share of common stock (or pre-funded warrant) was sold at a public offering price of $1.00 per share (inclusive of the pre-funded warrant exercise price).
THAR Ratings Summary
THAR Quant Ranking